共 50 条
Implantable Cardiac Alert System for Early Recognition of ST-Segment Elevation Myocardial Infarction
被引:24
|作者:
Gibson, C. Michael
[1
]
Holmes, David
[2
]
Mikdadi, Ghiath
[3
]
Presser, Dale
[4
]
Wohns, David
[5
]
Yee, Megan K.
[1
]
Kaplan, Andrew
[6
]
Ciuffo, Allen
[7
]
Eberly, Arthur L., III
[8
]
Iteld, Bruce
[9
]
Krucoff, Mitchell W.
[10
,11
]
机构:
[1] Harvard Med Sch, Div Cardiovasc Med, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA
[2] Mayo Clin, Dept Cardiovasc Med, Rochester, MN USA
[3] Heart Clin Hammond, Hammond, LA USA
[4] Innovat Med Res LLC, Covington, LA USA
[5] Frederick Meijer Heart & Vasc Inst, Div Cardiovasc Med, Spectrum Hlth, Grand Rapids, MI USA
[6] Banner Heart Hosp, Mesa, AZ USA
[7] Sentara Healthcare Norfolk, Norfolk, VA USA
[8] Greenville Hlth Syst, Div Cardiol, Dept Internal Med, Greenville, SC USA
[9] Louisiana Heart Ctr, Hammond, LA USA
[10] Duke Univ, Med Ctr, Durham, NC USA
[11] Duke Clin Res Inst, Durham, NC USA
关键词:
acute coronary syndrome;
implantable monitoring device;
ST-segment elevation myocardial infarction;
symptom-to-door time;
TO-BALLOON TIME;
EMERGENCY MEDICAL-SERVICES;
INTRACARDIAC ELECTROGRAM;
MORTALITY;
ONSET;
PREVALENCE;
DELAY;
INTERVENTION;
ANGIOPLASTY;
THROMBOSIS;
D O I:
10.1016/j.jacc.2019.01.014
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
BACKGROUND Symptoms remain a poor prompt for acute coronary syndromes (ACS). Timely restoration of perfusion in ST-segment elevation myocardial infarction is associated with improved left ventricular function and survival. OBJECTIVES This report details the results of ALERTS (AngelMed for Early Recognition and Treatment of STEMI), a multicenter, randomized trial of an implantable cardiac monitor that alerts patients with rapidly progressive ST-segment deviation. METHODS High-risk ACS subjects (N = 907) were randomized to a control (alarms deactivated) or treatment group for 6 months, after which alarms were activated in all subjects. The primary safety endpoint was absence of system-related complications (>90%). The composite primary efficacy endpoint was cardiac/unexplained death, new Q-wave myocardial infarction, or detection to presentation time >2 h. RESULTS Safety was met with 96.7% freedom from system-related complications (n = 30). The efficacy endpoint for a confirmed occlusive event within 7 days was not significantly reduced in the treatment compared with control group (16 of 423 [3.8%] vs. 21 of 428 [4.9%], posterior probability = 0.786). Within a 90-day window, alarms significantly decreased detection to arrival time at a medical facility (51 min vs. 30.6 h; Pr [pt < pc] >0.999). In an expanded analysis using data after the randomized period, positive predictive value was higher (25.8% vs. 18.2%) and false positive rate significantly lower in the ALARMS ON group (0.164 vs. 0.678 false positives per patient-year; p < 0.001). CONCLUSIONS The implantable cardiac system detects early ST-segment deviation and alerts patients of a potential occlusive event. Although the trial did not meet its pre-specified primary efficacy endpoint, results suggest that the device may be beneficial among high-risk subjects in potentially identifying asymptomatic events. (AngelMed for Early Recognition and Treatment of STEMI [ALERTS]; NCT00781118) (C) 2019 by the American College of Cardiology Foundation.
引用
收藏
页码:1919 / 1927
页数:9
相关论文